Physician profile
Lilly Gonzalez
NPI 1558604058
$4,297.46
in general payments reported to CMS, 2019-2025
30 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $596 · 2023: $807 · 2024: $1,143 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.66 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.73 | 2021-2025 | |
| Celgene Corporation | $633.62 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $426.36 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.00 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $276.36 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $274.73 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $164.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $134.20 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $117.21 | 2021-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $108.67 | 2025 | Tremfya |
| Genzyme Corporation | $85.71 | 2025 | |
| Redhill Biopharma INC. | $80.60 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $59.48 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $58.23 | 2024-2025 | |
| Celltrion USA INC. | $45.95 | 2025 | Vegzelma |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $34.01 | 2023 | |
| Pharmacosmos Therapeutics INC. | $27.88 | 2023 | Monoferric |
| Merck Sharp & Dohme LLC | $26.18 | 2024 | Dificid |
| Pfizer INC. | $24.06 | 2025 | |
| Boston Scientific Corporation | $22.16 | 2022 | |
| Exact Sciences Corporation | $20.90 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $20.78 | 2023 | Linzess |
| Qol Medical, LLC | $20.00 | 2023 | Sucraid |
| Gilead Sciences, INC. | $18.47 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.25 | 2025 | Iqirvo |
| Novo Nordisk INC | $17.93 | 2022 | |
| Vivus LLC | $17.55 | 2022 | |
| Alfasigma USA, INC. | $15.52 | 2022 | |
| Evoke Pharma, INC. | $14.73 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $4.84 | 2023 | Cold Snare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.